BioMarin Pharmaceutical Inc.  (BMRN) Trade Now »     Rate BMRN  -  Discuss BMRN  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BMRN Analysis & Videos »


BMRN: Bull or Bear?

UpDown Virtual Investing: Earn Real Money with Zero Risk BMRN

76%

-2.86% in 9 days UpDown Virtual Investing: Earn Real Money with Zero Risk The ultimate risk/reward trade for virtual investing – its is free and easy to register at the UpDown and users can earn real money at the site in two ways. The first is by beating the market (S&P 500 Index) on a monthly basis and the second is by referring investors. However, the referral system is designed to encourage legitamte referals only by basing the payment on how much the referred person earns on the site. So, if you refer someone who earns $100, you will receive 10% or $10 as a referral bonu ... Continue reading »

By  Mike Havrilla   (-2.97%  risk: moderate)  11/23/08

Comment

A New Index of Emerging Biotech & Pharma Companies BMRN

76%

+0.00% in 24 hours (closed on 11/23/08) A New Index of Emerging Biotech & Pharma Companies The accompanying table includes the Top 40 rated companies in the ETF Innovators [ETFI] Emerging Bio-Pharma Index, which includes U.S.-listed companies with market caps between $150M-$1.5B and factors in each companies approved products, late-stage clinical pipeline, trailing 52-week stock price performance, and market cap weighting to calculate a stock rating. The index has performed much better than its peers over the past year for both the Top 40 Rated (-9%) and all 76 companies (-15%) – doing bett ... Continue reading »

By  Mike Havrilla   (-2.97%  risk: moderate)  11/22/08

Comment

Bullish on BMRN ... BMRN

66%

-19.16% in 34 days BUSINESS SUMMARY BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company�s product portfolio comprises approved products and multiple investigational product candidates. Its approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase ind... Continue reading »

By  Marian Filo   (-30.03%  risk: aggressive)  10/29/08

Comment

Biotech Blues: Four Stocks on Sale with Hope BMRN

76%

-11.33% in 28 days (closed on 11/22/08) Biotech Blues: Four Stocks on Sale with Hope The following group of biotech companies have market caps of at least $300M with a one year stock price change that is below the iShares Nasdaq Biotech ETF (IBB) loss of 21.8% (Source: Google Finance, 10/25/08) with potential upside catalysts over the next year. Alnylam Pharma (ALNY): $872M, -31.6% Biogen Idec (BIIB): $12B, -48.4% BioMarin Pharma (BMRN): $1.7B, -33% Momenta Pharma (MNTA): $348M, -23.4% Momenta and Novartis (NVS) expect to launch a generic version (M-Enoxaparin) of the injectable ... Continue reading »

By  Mike Havrilla   (-2.97%  risk: moderate)  10/25/08

Comment

Who's Next in the Biotech Buyout Frenzy? BMRN

76%

-16.63% in 12 days (closed on 10/25/08) Who's Next in the Biotech Buyout Frenzy? The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms. Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClo ... Continue reading »

By  Mike Havrilla   (-2.97%  risk: moderate)  10/13/08

Comment

BioMarin Now a Core Biotech BMRN

-59.05% in 174 days We believe that the company is making steady progress on a number of candidates in its pipeline. Continue reading »

By  Zacks.com   (-24.32%  risk: conservative)  06/11/08

Comment

strong top-line growth and raised guidance BMRN

22%

-59.89% in 215 days BioMarin Pharmaceutical Inc. develops enzyme therapies for serious chronic genetic disorders and other diseases and conditions. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI. Recently, the company received FDA approval for its third product, Kuvan, for the treatment of PKU. Strong sales of Kuvan, coupled with accelerating sales of both Aludrazyme and Naglazyme, will drive the company to profitability in 2008 and beyond. As such, we maintain our ... Continue reading »

By  Armin Stuk   (-35.01%  risk: conservative)  05/01/08

Comment

Kuvan sales... BMRN

25%

+2.64% in 3 days (closed on 01/25/08) Biomarin has had a huge upturn do to FDA approval of Kuvan. Even with this higher price I still remain bearish. If insurance companies approve Kuvan, and if it succeeds in treatment of PKU. We should still see solid growth with the combination of solid sales of Naglazyme and Aldurazyme. Continue reading »

By  Drew   (-17.04%  risk: conservative)  01/22/08

Comment

People Bullish on BMRN

Mike Havrilla Principal 76% 8 days ago	Marian Filo Principal 66% about 1 mo ago	rossty Analyst 86% about 1 mo ago
Jeremy McDonald Associate 77% about 1 mo ago	Mavaron Liang Analyst 47% 5 mos ago

People Bearish on BMRN

monster Analyst 89% 5 mos ago

Trade BMRN Now
and Get 30 Free Trades »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.